Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy

Rates of persistent viremia (PV) while on direct-acting antiviral therapy were low (5.7%) in a real-world cohort of 983 patients. High sustained virologic response rates were achieved both in patients with PV (92.9%) and those with rapid virologic response (96.5%), without significant differences.

Detalles Bibliográficos
Autores principales: Carver, Alicia B, Zuckerman, Autumn D, DeClercq, Joshua, Choi, Leena, Chastain, Cody A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770330/
https://www.ncbi.nlm.nih.gov/pubmed/33409333
http://dx.doi.org/10.1093/ofid/ofaa569
_version_ 1783629485817462784
author Carver, Alicia B
Zuckerman, Autumn D
DeClercq, Joshua
Choi, Leena
Chastain, Cody A
author_facet Carver, Alicia B
Zuckerman, Autumn D
DeClercq, Joshua
Choi, Leena
Chastain, Cody A
author_sort Carver, Alicia B
collection PubMed
description Rates of persistent viremia (PV) while on direct-acting antiviral therapy were low (5.7%) in a real-world cohort of 983 patients. High sustained virologic response rates were achieved both in patients with PV (92.9%) and those with rapid virologic response (96.5%), without significant differences.
format Online
Article
Text
id pubmed-7770330
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77703302021-01-05 Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy Carver, Alicia B Zuckerman, Autumn D DeClercq, Joshua Choi, Leena Chastain, Cody A Open Forum Infect Dis Brief Reports Rates of persistent viremia (PV) while on direct-acting antiviral therapy were low (5.7%) in a real-world cohort of 983 patients. High sustained virologic response rates were achieved both in patients with PV (92.9%) and those with rapid virologic response (96.5%), without significant differences. Oxford University Press 2020-11-26 /pmc/articles/PMC7770330/ /pubmed/33409333 http://dx.doi.org/10.1093/ofid/ofaa569 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Reports
Carver, Alicia B
Zuckerman, Autumn D
DeClercq, Joshua
Choi, Leena
Chastain, Cody A
Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy
title Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy
title_full Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy
title_fullStr Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy
title_full_unstemmed Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy
title_short Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy
title_sort incidence and impact of persistent viremia on svr rates in patients receiving direct-acting antiviral therapy
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770330/
https://www.ncbi.nlm.nih.gov/pubmed/33409333
http://dx.doi.org/10.1093/ofid/ofaa569
work_keys_str_mv AT carveraliciab incidenceandimpactofpersistentviremiaonsvrratesinpatientsreceivingdirectactingantiviraltherapy
AT zuckermanautumnd incidenceandimpactofpersistentviremiaonsvrratesinpatientsreceivingdirectactingantiviraltherapy
AT declercqjoshua incidenceandimpactofpersistentviremiaonsvrratesinpatientsreceivingdirectactingantiviraltherapy
AT choileena incidenceandimpactofpersistentviremiaonsvrratesinpatientsreceivingdirectactingantiviraltherapy
AT chastaincodya incidenceandimpactofpersistentviremiaonsvrratesinpatientsreceivingdirectactingantiviraltherapy

Ejemplares similares